ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Division Spotlight
Aerospace Nuclear Science & Technology
Organized to promote the advancement of knowledge in the use of nuclear science and technologies in the aerospace application. Specialized nuclear-based technologies and applications are needed to advance the state-of-the-art in aerospace design, engineering and operations to explore planetary bodies in our solar system and beyond, plus enhance the safety of air travel, especially high speed air travel. Areas of interest will include but are not limited to the creation of nuclear-based power and propulsion systems, multifunctional materials to protect humans and electronic components from atmospheric, space, and nuclear power system radiation, human factor strategies for the safety and reliable operation of nuclear power and propulsion plants by non-specialized personnel and more.
Meeting Spotlight
Nuclear Energy Conference & Expo (NECX)
September 8–11, 2025
Atlanta, GA|Atlanta Marriott Marquis
Standards Program
The Standards Committee is responsible for the development and maintenance of voluntary consensus standards that address the design, analysis, and operation of components, systems, and facilities related to the application of nuclear science and technology. Find out What’s New, check out the Standards Store, or Get Involved today!
Latest Magazine Issues
Jun 2025
Jan 2025
Latest Journal Issues
Nuclear Science and Engineering
August 2025
Nuclear Technology
Fusion Science and Technology
July 2025
Latest News
Orano Med expands its Texas Pb-212 R&D center
Orano Group subsidiary Orano Med, a developer of targeted alpha therapies for oncology, inaugurated the expansion of its main research and development center located in Plano, Texas. The facility is used in the development of radiopharmaceuticals and for conducting preclinical research focused on targeted alpha therapies using lead-212, an alpha-emitting radioisotope that has shown promise in treating various types of cancer.
Andrea Pola (Politecnico di Milano), Davide Mazzucconi (Politecnico di Milano), Davide Bortot (Politecnico di Milano), Alessandro Porta (Politecnico di Milano), Stefano Agosteo (Politecnico di Milano)
Proceedings | ICRS 14/RPSD 2022 | Seattle, WA, September 25-29, 2022 | Pages 58-61
